📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs
Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.
Key Highlights
Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.
Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.
Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.
9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.
Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.
💼 Action for Investors
Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.
Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%
Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.
Key Highlights
Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.
Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.
The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.
9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.
Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.
💼 Action for Investors
Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.
Concord Biotech Q3 Revenue Up 14% to Rs 278 Cr; EBITDA Margins Impacted by Expansion Costs
Concord Biotech reported a 14% YoY revenue growth in Q3FY26, reaching Rs 278 crore, primarily driven by a 24% surge in the API segment. However, PAT declined by 16% YoY to Rs 64 crore due to commercialization expenses for the new injectable facility and setup costs for its US subsidiary, Stellon Biotech. EBITDA margins compressed to 35.6% from 40.1% a year ago, though normalized margins remain healthy at approximately 40%. The company achieved a significant milestone by receiving WHO-GMP certification for its injectable plant, paving the way for domestic market entry.
Key Highlights
Q3FY26 Revenue grew 14% YoY to Rs 278 crore, led by robust 24% growth in the API segment.
EBITDA margins stood at 35.6%, impacted by one-time setup costs; normalized margins are at ~40%.
Received WHO-GMP certification for Unit 4 (Injectable facility), enabling domestic brand launches.
Established US subsidiary Stellon Biotech Inc. to create a direct commercial footprint in the US market.
Appointed Raviraj Karia as the new Chief Financial Officer (CFO) with 23+ years of experience.
💼 Action for Investors
Investors should monitor the ramp-up of the new injectable facility and the performance of the US subsidiary, as these are the primary drivers for future growth despite current margin pressure. The long-term outlook remains positive due to specialized fermentation capabilities and global expansion.
Concord Biotech Approves Q3 FY26 Results; Appoints New Company Secretary
Concord Biotech's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, BSR & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting concerns. Additionally, the company appointed Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer effective February 11, 2026. This appointment fills a key managerial personnel (KMP) role to oversee corporate governance and regulatory filings.
Key Highlights
Board approved unaudited financial results for the third quarter and nine months ended December 31, 2025.
Statutory auditors M/s. BSR & Co. LLP issued a Limited Review Report with an Unmodified Opinion.
Mr. Paritosh Trivedi appointed as Company Secretary, Compliance Officer, and Nodal Officer.
The new appointee brings 5 years of experience in corporate compliance across Textile, IT, and FMCG sectors.
The board meeting concluded at 6:22 P.M. on February 11, 2026.
💼 Action for Investors
Investors should examine the detailed financial tables once published to assess revenue and margin performance for Q3. The appointment of a new compliance officer is a routine administrative update and does not impact the company's fundamental value.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Experience
Concord Biotech has appointed Mr. Raviraj Karia as its new Chief Financial Officer, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of experience in the pharmaceutical and healthcare sectors, having held leadership roles at Intas Pharmaceuticals and Claris Lifesciences. His expertise spans multi-billion dollar financing, large-scale M&A, and cost-efficiency programs. This strategic appointment is aimed at strengthening the company's financial discipline and governance as it scales.
Key Highlights
Appointment of Mr. Raviraj Karia as CFO and Key Managerial Personnel effective December 18, 2025
Brings over 23 years of experience in pharmaceuticals, healthcare, and private equity sectors
Previously managed multi-billion dollar financing programs and led major outbound pharma acquisitions
Proven track record of reducing borrowing costs by 2-3% annually through financial optimization
Expertise in implementing digital tools like SAP-based MIS and Power BI for financial governance
💼 Action for Investors
Investors should view this as a positive move for corporate governance and financial strategy. Monitor the company's future capital allocation and cost-efficiency metrics under the new leadership.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Finance Experience
Concord Biotech Limited has appointed Mr. Raviraj Karia as its Chief Financial Officer (CFO) and Key Managerial Personnel, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of extensive experience in the pharmaceutical, healthcare, and clinical research sectors. He has previously held leadership roles at prominent firms such as Intas Pharmaceuticals, Claris Lifesciences, and Shalby Hospitals. His expertise includes managing multi-billion dollar financing programs and executing large-scale outbound acquisitions, which is expected to strengthen the company's financial governance.
Key Highlights
Mr. Raviraj Karia appointed as CFO and Key Managerial Personnel effective December 18, 2025.
Brings over 23 years of experience across pharmaceuticals, healthcare, and private equity sectors.
Proven track record in managing multi-billion dollar financing and reducing borrowing costs by 2-3% annually in previous roles.
Expertise in M&A, having led India’s largest outbound pharma acquisition during his career.
Previous leadership experience at Intas Pharmaceuticals, Sakar Healthcare, and Lambda Therapeutics.
💼 Action for Investors
Investors should view this as a positive step in strengthening the leadership team; monitor the company's financial strategy and capital allocation under the new CFO.